Jacques Gonella is drawing on 30 years of experience in drug delivery, industrial development and transaction management.
Jacques Gonella served on the Board of Directors of NASDAQ-listed company Antares Pharma Inc. from 2001 to 2019, and served as Chairman of the Board of Directors from 2001 to 2008.
Jacques Gonella founded Permatec (a Swiss company which merged with Medi-Ject, Inc. to form Antares Pharma, Inc.) and had served as Chairman of the Board of Directors of Permatec from its founding in June 1997. Prior to founding Permatec, Dr Gonella founded JAGO Pharma AG in 1983 and served as its President and Chief Executive Officer until its acquisition in 1996 by SkyePharma, PLC, a United Kingdom company listed on the London Stock Exchange and quoted on NASDAQ.
Prior to founding JAGO, Jacques Gonella occupied various positions with F. Hoffmann-La Roche Ltd. and Pfizer Inc.
He has also served as a member of the Board of Directors of Protherics PLC, London and he serves on the Board of Directors of several private companies. He is a private investor and is proprietor of NobleHouse Consulting Ltd., Hong Kong.
Jacques Gonella holds a doctorate in analytical chemistry from the Polytechnic Institute of Lausanne, Switzerland.